[{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "619 949 3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 579, "companyOfficers": [{"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 68, "title": "President & Director", "yearBorn": 1956, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 285000, "exercisedValue": 0, "unexercisedValue": 6744174}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 332619, "exercisedValue": 0, "unexercisedValue": 18899056}, {"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 59, "title": "Senior Vice President of Science", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 397945, "exercisedValue": 0, "unexercisedValue": 3216}, {"maxAge": 1, "name": "Mr. Ping  Zhang", "age": 51, "title": "Interim CEO & Executive Chair", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.23, "open": 8.35, "dayLow": 8.11, "dayHigh": 8.35, "regularMarketPreviousClose": 8.23, "regularMarketOpen": 8.35, "regularMarketDayLow": 8.11, "regularMarketDayHigh": 8.35, "payoutRatio": 0.0, "trailingPE": 408.5, "forwardPE": 17.76087, "volume": 43547, "regularMarketVolume": 43547, "averageVolume": 94117, "averageVolume10days": 90080, "averageDailyVolume10Day": 90080, "bid": 5.84, "ask": 10.53, "bidSize": 2, "askSize": 2, "marketCap": 742054784, "fiftyTwoWeekLow": 6.11, "fiftyTwoWeekHigh": 19.0, "allTimeHigh": 47990.25, "allTimeLow": 2.85, "priceToSalesTrailing12Months": 7.2615914, "fiftyDayAverage": 7.8024, "twoHundredDayAverage": 8.926, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 726499776, "profitMargins": 0.040760003, "floatShares": 20459640, "sharesOutstanding": 90826777, "sharesShort": 1502320, "sharesShortPriorMonth": 1618588, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0165, "heldPercentInsiders": 0.87162, "heldPercentInstitutions": 0.03778, "shortRatio": 14.95, "shortPercentOfFloat": 0.0987, "impliedSharesOutstanding": 91493804, "bookValue": 1.013, "priceToBook": 8.065153, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "earningsQuarterlyGrowth": -0.875, "netIncomeToCommon": 4165000, "trailingEps": 0.02, "forwardEps": 0.46, "lastSplitFactor": "1:15", "lastSplitDate": 1698710400, "enterpriseToRevenue": 7.109, "enterpriseToEbitda": 63.383, "52WeekChange": -0.4322446, "SandP52WeekChange": 0.16625166, "lastDividendValue": 3.6, "lastDividendDate": 1673568000, "quoteType": "EQUITY", "currentPrice": 8.17, "targetHighPrice": 20.0, "targetLowPrice": 16.0, "targetMeanPrice": 18.0, "targetMedianPrice": 18.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 54365000, "totalCashPerShare": 0.599, "ebitda": 11462000, "totalDebt": 1393000, "quickRatio": 4.682, "currentRatio": 5.395, "totalRevenue": 102189000, "debtToEquity": 1.076, "revenuePerShare": 1.181, "returnOnAssets": 0.042680003, "returnOnEquity": 0.07842, "grossProfits": 98009000, "freeCashflow": 517125, "operatingCashflow": 927000, "earningsGrowth": -0.628, "revenueGrowth": 0.061, "grossMargins": 0.9591, "ebitdaMargins": 0.11216, "operatingMargins": 0.08113, "financialCurrency": "USD", "symbol": "GYRE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NCM", "messageBoardId": "finmb_100542295", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "longName": "Gyre Therapeutics, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1761342997, "regularMarketTime": 1761336002, "shortName": "Gyre Therapeutics, Inc.", "regularMarketChangePercent": -0.729034, "regularMarketPrice": 8.17, "earningsTimestampStart": 1762804800, "earningsTimestampEnd": 1762804800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.02, "epsForward": 0.46, "epsCurrentYear": 0.05, "priceEpsCurrentYear": 163.4, "fiftyDayAverageChange": 0.36759996, "fiftyDayAverageChangePercent": 0.0471137, "twoHundredDayAverageChange": -0.75599957, "twoHundredDayAverageChangePercent": -0.084696345, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1144848600000, "postMarketChangePercent": -0.244804, "postMarketPrice": 8.15, "postMarketChange": -0.0200005, "regularMarketChange": -0.0599995, "regularMarketDayRange": "8.11 - 8.35", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 94117, "fiftyTwoWeekLowChange": 2.06, "fiftyTwoWeekLowChangePercent": 0.33715218, "fiftyTwoWeekRange": "6.11 - 19.0", "fiftyTwoWeekHighChange": -10.83, "fiftyTwoWeekHighChangePercent": -0.57, "fiftyTwoWeekChangePercent": -43.22446, "dividendDate": 1673481600, "displayName": "Gyre Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-25"}]